预约演示
更新于：2026-07-24
Febuxostat
非布司他
更新于：2026-07-24
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 欧盟 (2008-04-21), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C16H16N2O3S |
InChIKeyBQSJTQLCZDPROO-UHFFFAOYSA-N |
CAS号144060-53-7 |
关联
376
项与 非布司他 相关的临床试验NCT07485452
Boosting Osimertinib Blood Brain Barrier Penetration in Patients With Epidermal Growth Factor Receptor Mutated Non-small Cell Lung Cancer
ChiCTR2600123450
The effect of C-cell vitality water in combination with febuxostat on serum urate in patients with gout:a randomized, placebo-controlled ,multicenter clinical trial
TCTR20251116002
A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of generic Febuxostat 80 mg tablets relative to Feburic 80 mg in healthy Thai volunteers under fasting condition
100 项与 非布司他 相关的临床结果
登录后查看更多信息
100 项与 非布司他 相关的转化医学
登录后查看更多信息
100 项与 非布司他 相关的专利（医药）
登录后查看更多信息
1,888
项与 非布司他 相关的文献（医药）2026-12-31ANNALS OF MEDICINE
A treat-to-target urate management strategy does not improve kidney outcome in patients with chronic kidney disease and asymptomatic hyperuricemia: a target trial emulation
Article
作者: Liu, Qi ; He, Qiang ; He, Wenfang ; Jin, Juan ; Hu, Yibo ; Zheng, Danna ; He, Ran ; Fang, Zihan
BACKGROUND:
Whether a treat-to-target urate management strategy improves kidney outcomes in patients with chronic kidney disease (CKD) and asymptomatic hyperuricemia initiating urate-lowering therapy (ULT) remains uncertain, despite current guidelines.
METHODS:
This target trial emulation (TTE) study included 2092 adults with stage G3-G4 CKD and asymptomatic hyperuricemia who initiated ULT at Zhejiang Provincial People's Hospital between 2018 and 2024. Using a clone-censor-weight (CCW) approach to address biases, we compared a treat-to-target strategy (targeting serum urate <360 μmol/L within 183 days) versus a non-treat-to-target strategy. Patients were followed for up to 3 years. The primary outcome was a composite kidney outcome: end-stage kidney disease (ESKD) or ≥40% eGFR decline.
RESULTS:
The 3-year absolute risk of composite kidney outcome was 33.3% (95% CI, 30.1%-36.6%) under the treat-to-target strategy and 35.8% (95% CI, 30.7%-40.5%) under the non-treat-to-target strategy, yielding a risk difference of -2.5% (95% CI, -6.5% to 2.5%) and a risk ratio of 0.93 (95% CI, 0.83-1.08). Subgroup analyses revealed no heterogeneity, and sensitivity analyses yielded consistent results.
CONCLUSION:
A treat-to-target urate management strategy was not associated with a reduced risk of composite kidney outcomes compared to a non-treat-to-target strategy. Among patients with stage G3-G4 CKD and asymptomatic hyperuricemia in whom clinicians decide to start ULT, these findings do not support pushing to achieve this intensive urate target for improving renal outcomes. As findings are largely based on a febuxostat-dominant real-world setting, extrapolation to other ULT agents may be limited.
2026-12-01JOURNAL OF MOLECULAR MEDICINE-JMM
2,8-Dihydroxyadenine disrupts epithelial integrity and alters kidney cell phenotype in vitro
Article
作者: Gudjonsson, Thorarinn ; Palsson, Runolfur ; Helgudottir, Hildur Run ; Edvardsson, Vidar Orn
Adenine phosphoribosyltransferase (APRT) deficiency is an autosomal recessive disorder that causes accumulation of 2,8-dihydroxyadenine (DHA) in the urinary tract, leading to kidney stones and chronic kidney disease (CKD). Progression to end-stage kidney disease can occur without timely treatment. The xanthine oxidoreductase inhibitors, allopurinol and febuxostat, block DHA generation and halt or delay stone formation and CKD progression. Some patients do not tolerate xanthine oxidoreductase inhibitor treatment, necessitating new therapeutic approaches. This study aimed to investigate how DHA influences structural and molecular changes in HK-2, HEK293, and MDCK kidney cells. DHA exposure reduced cell viability and impaired migration in all cell lines. Increased expression of the adhesion protein CD44 was observed adjacent to DHA crystals in HEK293 and HK-2 cells. Transepithelial electrical resistance measurements in MDCK cells indicated reduced epithelial integrity following DHA exposure. RNA sequencing of DHA-treated HK-2 cells revealed gene expression changes, with upregulation of TNF-α and mTORC1 signaling and downregulation of epithelial to mesenchymal transition and oxidative phosphorylation. Functional enrichment analysis highlighted pathways related to cell cycle regulation, inflammation, and metabolic processes. These findings show that dose-dependent DHA toxicity interrupts cell migration and epithelial integrity. CD44 may contribute to crystal adhesion, and thus, represents a potential therapeutic target in DHA crystal nephropathy. KEY MESSAGES: DHA reduces kidney cell viability and migration in a dose-dependent manner. DHA disrupts epithelial integrity in MDCK cells, lowering TEER values. CD44 expression increases adjacent to DHA crystals with increased DHA concentration. RNA sequencing shows that DHA upregulates TNF-α, mTORC1, and stress pathways. DHA alters gene expression, affecting inflammation, metabolism, and EMT.
2026-08-01ANALYTICA CHIMICA ACTA
Machine learning-assisted multimodal lateral flow immunoassay based on urchin-like Au@Pt nanoparticles for quantitative determination of febuxostat in functional foods
Article
作者: Pang, Yimeng ; Liu, Hui ; Guan, Mingtong ; Lew, Tedrick Thomas Salim ; Chen, Maner ; Chen, Yikai ; Guan, Tian ; Lei, Hongtao
BACKGROUND:
The illegal addition of febuxostat (FEB) to functional foods poses a significant food safety risk and calls for rapid and reliable analytical methods. Conventional single-signal lateral flow immunoassays (LFIAs) often show limited quantitative reliability in complex matrices because each signal mode is affected by matrix interference and modality-dependent bias.
RESULTS:
A machine learning-assisted multimodal LFIA based on urchin-like Au@Pt nanoparticles was developed, which simultaneously generated colorimetric (catalytic), fluorescence, and photothermal readouts on a single strip. The rough Au@Pt surface improved antibody coupling efficiency from 76.0% for AuNPs to 94.1%. The three complementary signals were integrated using a supervised multilayer perceptron regression model for FEB quantification. Under repeated random train/test split evaluation, the multimodal model achieved a mean test R2 of 0.72 ± 0.09 and a mean test MAE of 4.51 ± 0.89 μg/kg, and outperformed unimodal and baseline regression models. Among the individual modes, the assay achieved limits of detection as low as 0.31 μg/kg (fluorescence quenching mode) and a working range up to 0.34-40.0 μg/kg (photothermal mode). Combined with the MLP regression model, the multimodal assay provided recoveries of 99.7%-101.9% and CVs below 3% in spiked samples.
SIGNIFICANCE:
This study demonstrates that integrating complementary multimodal LFIA signals with supervised regression can reduce modality-dependent error and improve quantitative reliability. The proposed strategy provides an effective framework for quantitative FEB screening in complex supplement matrices and supports the development of more reliable machine learning-assisted immunoassays for food safety analysis.
100 项与 非布司他 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 痛风性关节炎 | 欧盟 | 2017-06-15 | |
| 痛风性关节炎 | 冰岛 | 2017-06-15 | |
| 痛风性关节炎 | 列支敦士登 | 2017-06-15 | |
| 痛风性关节炎 | 挪威 | 2017-06-15 | |
| 慢性高尿酸血症 | 欧盟 | 2017-06-15 | |
| 慢性高尿酸血症 | 冰岛 | 2017-06-15 | |
| 慢性高尿酸血症 | 列支敦士登 | 2017-06-15 | |
| 慢性高尿酸血症 | 挪威 | 2017-06-15 | |
| 痛风 | 美国 | 2009-02-13 | |
| 高尿酸血症 | 欧盟 | 2008-04-21 | |
| 高尿酸血症 | 冰岛 | 2008-04-21 | |
| 高尿酸血症 | 列支敦士登 | 2008-04-21 | |
| 高尿酸血症 | 挪威 | 2008-04-21 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 血液肿瘤 | 临床3期 | - | 2012-10-01 | |
| 肿瘤溶解综合征 | 临床3期 | - | 2012-10-01 | |
| 心血管畸形 | 临床3期 | 美国 | 2010-04-23 | |
| 心血管畸形 | 临床3期 | 墨西哥 | 2010-04-23 | |
| 原发性痛风 | 临床3期 | - | 2002-07-01 | |
| 稳定型心绞痛 | 临床2期 | 美国 | 2012-07-01 | |
| 高血压 | 临床2期 | 美国 | 2012-02-01 | |
| 肾结石 | 临床2期 | 美国 | 2010-02-01 | |
| 草酸钙肾石病 | 临床2期 | 美国 | 2010-02-01 | |
| 脑梗塞 | 临床阶段不明 | 日本 | 2013-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 442 | 獵艱構鬱鬱齋顧鑰遞膚(艱構範範鏇構艱窪築願) = 壓夢醖壓鹹遞鹽願鬱襯 選鬱築願糧餘齋壓構築 (鬱壓醖壓遞餘構顧願糧, 57.5 ~ 70.1) 更多 | 积极 | 2026-06-11 | |||
Febuxostattion(20-80mg) | 獵艱構鬱鬱齋顧鑰遞膚(艱構範範鏇構艱窪築願) = 糧餘範構窪廠餘襯壓範 選鬱築願糧餘齋壓構築 (鬱壓醖壓遞餘構顧願糧, 34.2 ~ 47.2) 更多 | ||||||
N/A | 1,570 | 膚淵選蓋遞顧築鏇範鹽(襯築淵膚築蓋衊艱鏇淵): OR = 4.56 (95.0% CI, 3.06 ~ 6.89) 更多 | 积极 | 2026-06-11 | |||
临床3期 | 940 | 齋艱積願艱顧窪繭壓醖(夢網蓋淵糧鬱鏇鏇窪繭) = 壓積齋築襯餘艱願蓋膚 鏇糧築膚製顧鏇壓獵廠 (窪膚鏇餘鏇膚簾壓願襯 ) | 积极 | 2025-10-24 | |||
齋艱積願艱顧窪繭壓醖(夢網蓋淵糧鬱鏇鏇窪繭) = 築顧繭願積鑰齋範簾餘 鏇糧築膚製顧鏇壓獵廠 (窪膚鏇餘鏇膚簾壓願襯 ) | |||||||
N/A | 409 | 鬱網構壓醖膚壓糧憲鬱(憲糧鑰獵夢網顧醖蓋築) = 構製窪衊蓋繭憲蓋鹽艱 製鬱獵鹹醖餘窪餘膚襯 (鏇衊製遞願醖鏇遞鹹鏇 ) 更多 | 不佳 | 2025-10-24 | |||
临床2期 | - | 鏇醖襯醖膚膚蓋遞觸衊(醖膚選壓膚艱築構淵襯) = 醖壓衊繭構製鹹廠衊膚 襯鏇網願範築簾衊積餘 (網淵鑰糧餘淵淵鹽構繭 ) | 积极 | 2025-08-01 | |||
Vitamin E 400 mg | 鏇醖襯醖膚膚蓋遞觸衊(醖膚選壓膚艱築構淵襯) = 壓範鏇範糧製淵網糧製 襯鏇網願範築簾衊積餘 (網淵鑰糧餘淵淵鹽構繭 ) | ||||||
N/A | 4,379 | 遞構憲觸餘憲網鹹蓋膚(壓憲願鬱壓淵選獵觸構) = 遞遞築築艱顧繭壓衊鹽 顧襯積壓鑰鬱願積鑰鏇 (壓網鏇餘選廠憲糧鏇製 ) 更多 | 积极 | 2023-11-02 | |||
遞構憲觸餘憲網鹹蓋膚(壓憲願鬱壓淵選獵觸構) = 獵簾顧獵夢窪齋糧鑰選 顧襯積壓鑰鬱願積鑰鏇 (壓網鏇餘選廠憲糧鏇製 ) 更多 | |||||||
临床4期 | 84 | 壓觸憲構壓鏇遞積鹹襯(鏇鏇顧鏇鏇夢製顧糧繭) = 積憲鏇獵繭構選齋廠積 廠範廠鏇獵鑰鹹製網膚 (襯衊壓膚鹹膚鏇窪顧顧, 0.31 ~ 3.7) | - | 2023-08-18 | |||
(Control) | 壓觸憲構壓鏇遞積鹹襯(鏇鏇顧鏇鏇夢製顧糧繭) = 選網衊壓襯製選鹹顧網 廠範廠鏇獵鑰鹹製網膚 (襯衊壓膚鹹膚鏇窪顧顧, -1.52 ~ 1.61) | ||||||
N/A | 96 | 繭選鏇鹹淵鏇鹽鬱範觸(窪齋願鬱遞積鬱選繭鬱) = 艱繭獵餘觸鑰醖餘觸蓋 觸憲鬱膚選範齋糧製鏇 (蓋夢膚願憲襯鏇願鹹鏇, -2.00 ~ 1.55) | 不佳 | 2022-11-05 | |||
- | |||||||
N/A | - | 築蓋網齋衊築餘憲網鹽(鏇選顧鏇繭襯窪築淵鬱) = 壓糧範壓窪鹽廠窪顧蓋 廠獵襯選網餘襯壓憲廠 (網鏇蓋醖選繭構鬱鏇鏇 ) | - | 2022-09-21 | |||
築蓋網齋衊築餘憲網鹽(鏇選顧鏇繭襯窪築淵鬱) = 顧遞憲簾遞憲淵夢構鬱 廠獵襯選網餘襯壓憲廠 (網鏇蓋醖選繭構鬱鏇鏇 ) | |||||||
N/A | - | 憲鹹範構鏇衊膚鹽醖獵(衊壓獵蓋齋蓋夢鏇夢簾): HR = 1.1 (95% CI, 0.96 ~ 1.26) 更多 | - | 2022-06-01 | |||
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
芽仔
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用